title: Application of proteomics in non-small-cell lung cancer.
abstract: Non-small-cell lung cancer (NSCLC) is a heterogeneous disease with diverse pathological features. Clinical proteomics allows the discovery of molecular markers and new therapeutic targets for this most prevalent type of lung cancer. Some of them may be used to detect early lung cancer, while others may serve as predictive markers of resistance to different therapies. Therapeutic targets and prognostic markers in NSCLC have also been discovered. These proteomics biomarkers may help to pair the individual NSCLC patient with the best treatment option. Despite the fact that implementation of these biomarkers in the clinic appears to be scarce, the recently launched Precision Medicine Initiative may encourage their translation into clinical practice.
authors.affiliation: a Department of Clinical Oncology , Queen Elizabeth Hospital , Kowloon , Hong Kong.
authors.forename: William C S
authors.initials: WC
authors.lastname: Cho
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism*; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000378:metabolism* / Q000628:therapy; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000378:metabolism* / Q000628:therapy; D011379:Prognosis; D020543:Proteome / Q000378:metabolism*; D040901:Proteomics; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D020543:Proteome
keywords: biomarker; diagnosis; non-small-cell lung cancer; prognosis; proteomics; therapeutic target·treatment response